Rostab EZ5 mg+10 mg

Established / FDA-approved uses

• Rostab EZ is indicated, as an adjunct to diet, for the treatment of primary hyperlipidemia (heterozygous familial and non-familial) and mixed dyslipidemia, in adult patients who are not adequately controlled on a statin alone or on ezetimibe alone, or in patients already treated with both components separately, to reduce elevated total cholesterol, LDL-cholesterol, apolipoprotein B, non-HDL-cholesterol, and triglycerides, and to increase HDL-cholesterol.

Guideline-supported use

• In patients with established atherosclerotic cardiovascular disease (ASCVD) or at high cardiovascular risk who do not reach LDL-cholesterol goals on maximally tolerated statin monotherapy, lipid guidelines support adding ezetimibe; Rostab EZ provides this statin plus ezetimibe combination in a single tablet to improve adherence.

Uses requiring combination therapy / adjunct positioning

• Rostab EZ is intended for use as an adjunct to a lipid-lowering diet, not as a substitute for dietary and lifestyle modification, and is generally reserved for patients in whom combination therapy (rather than either single agent) is judged appropriate by the prescribing physician.

Note: Rostab EZ is not indicated for isolated hypertriglyceridemia or for prevention of pancreatitis due to severe hypertriglyceridemia.

Rostab EZ is a fixed-dose combination oral lipid-lowering medicine that pairs a statin (rosuvastatin) with a cholesterol absorption inhibitor (ezetimibe) in a single tablet. It is used, together with diet and lifestyle changes, to lower total cholesterol, LDL-cholesterol ("bad" cholesterol), apolipoprotein B, non-HDL-cholesterol and triglycerides, and to raise HDL-cholesterol ("good" cholesterol) in adults with high cholesterol or mixed dyslipidemia.

By combining two complementary mechanisms of cholesterol lowering, Rostab EZ can produce greater LDL-cholesterol reduction than either component alone at a comparable dose, which may help patients who have not reached their target cholesterol levels on statin monotherapy.

Pharmacodynamics

Rosuvastatin + Ezetimibe lowers cholesterol through two complementary mechanisms. The rosuvastatin component is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts HMG-CoA to mevalonate, a precursor of cholesterol; this increases the number of hepatic LDL receptors, enhancing LDL uptake and catabolism, and reduces hepatic synthesis of VLDL. The ezetimibe component inhibits the intestinal absorption of dietary and biliary cholesterol at the brush border of the small intestine by blocking the Niemann-Pick C1-Like 1 (NPC1L1) sterol transporter, without affecting absorption of fat-soluble vitamins or triglycerides.

Pharmacokinetics

Rosuvastatin reaches peak plasma concentration in about 3–5 hours, has low absolute bioavailability (~20%) due to first-pass extraction, is minimally metabolized (mainly by CYP2C9), and is eliminated largely unchanged via the feces, with a plasma half-life of approximately 19 hours. Ezetimibe is absorbed and extensively conjugated to an active glucuronide in the intestinal wall and liver, undergoes enterohepatic recirculation, and is eliminated primarily in the feces, with a combined half-life (ezetimibe plus glucuronide) of approximately 22 hours.

Clinically significant interactions

• Cyclosporine: significantly increases rosuvastatin plasma concentrations; concurrent use with Rostab EZ should generally be avoided, and if unavoidable, the lowest rosuvastatin-containing strength should be used with close monitoring.
• Gemfibrozil and other fibrates, or niacin (≥1 g/day): increase the risk of myopathy and rhabdomyolysis when combined with Rostab EZ; combination should be avoided or used only with careful monitoring and lower statin dosing.
• Warfarin and other vitamin K antagonists: Rostab EZ may increase INR; INR should be monitored closely when therapy is started or the dose is changed.
• Antacids (aluminum/magnesium hydroxide): reduce rosuvastatin absorption if taken simultaneously with Rostab EZ; separate dosing by at least 2 hours.
• Bile acid sequestrants (e.g., cholestyramine): reduce absorption of the ezetimibe component of Rostab EZ; take Rostab EZ at least 2 hours before or 4 hours after a bile acid sequestrant.
• Other strong CYP inhibitors or transporter inhibitors that raise statin exposure may increase myopathy risk with Rostab EZ; discuss all concurrent medicines with your physician.

Most patients tolerate Rostab EZ well. Reported side effects include:

• Common: myalgia (muscle aches), headache, diarrhea (more often attributed to the ezetimibe component), nasopharyngitis, upper respiratory symptoms, and mild elevations in liver enzymes.
• Less common: nausea, abdominal pain, constipation, fatigue, arthralgia.
• Rare but serious: myopathy progressing to rhabdomyolysis (muscle breakdown, which can be serious and, rarely, fatal), clinically significant hepatotoxicity, and hypersensitivity reactions.

Seek prompt medical attention for unexplained muscle pain, tenderness or weakness, especially if accompanied by fever or dark urine, while taking Rostab EZ.

Pregnancy: Rostab EZ is contraindicated in pregnancy. The rosuvastatin component may cause fetal harm by reducing fetal cholesterol and other biologically important derivatives of cholesterol synthesis; women of childbearing potential should use effective contraception during treatment. If pregnancy occurs while taking Rostab EZ, discontinue it immediately and consult a physician.

Lactation: Rostab EZ is contraindicated during breastfeeding, as rosuvastatin is excreted into breast milk and there is a potential for serious adverse effects in nursing infants.

• Myopathy and rhabdomyolysis: Rostab EZ can rarely cause myopathy and, very rarely, life-threatening rhabdomyolysis with acute kidney injury, particularly at higher doses or when combined with interacting drugs (see Interactions). Report unexplained muscle pain, tenderness, or weakness promptly.
• Hepatotoxicity: elevations in liver transaminases can occur; liver function should be assessed before starting Rostab EZ and if symptoms of liver injury occur.
• New-onset diabetes: statins, including the rosuvastatin component, have been associated with increases in blood glucose and HbA1c; monitor patients at risk of diabetes.
• Renal effects: proteinuria and hematuria have been observed with rosuvastatin, generally transient; use the lowest effective dose in patients with renal impairment.
• Asian patients: rosuvastatin plasma levels are higher in patients of Asian ancestry; a lower starting dose of Rostab EZ should be considered.
• Avoid excessive alcohol intake, which increases the risk of liver and muscle toxicity with Rostab EZ.

There is no specific antidote for overdose of Rostab EZ. In the event of a suspected overdose, seek immediate medical attention or contact a poison control center. Management is supportive and symptomatic, including monitoring of liver function and creatine kinase, and general measures to support vital organ function; hemodialysis is not expected to be of significant benefit given the protein binding and pharmacokinetics of both components.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Renal impairment: no dose adjustment is generally needed in mild-to-moderate impairment; in severe renal impairment not requiring dialysis, start Rostab EZ at the lowest rosuvastatin-containing strength and avoid the highest strength.
• Hepatic impairment: contraindicated in active liver disease; use with caution and monitor liver enzymes in patients with a history of liver disease or heavy alcohol use.
• Elderly: no specific dose adjustment is required based on age alone, but elderly patients may be at higher risk of myopathy; use the lowest effective dose of Rostab EZ.
• Asian ancestry: higher rosuvastatin exposure has been observed; consider a lower starting dose.
• Pediatric patients: see Pediatric Uses.

Statin (HMG-CoA Reductase Inhibitor) + Cholesterol Absorption Inhibitor (Fixed-Dose Combination)

Rosuvastatin + Ezetimibe works via two complementary, non-overlapping mechanisms: rosuvastatin inhibits HMG-CoA reductase in the liver, reducing endogenous cholesterol synthesis and upregulating hepatic LDL receptors to clear LDL-cholesterol from the blood, while ezetimibe blocks the NPC1L1 transporter at the intestinal brush border to reduce absorption of dietary and biliary cholesterol. Together, these actions produce greater reductions in LDL-cholesterol than either agent alone.

X

The safety and efficacy of the fixed-dose combination Rostab EZ tablet have not been established in pediatric patients, and it is not recommended for use in children. Individual components have limited, specialist-supervised pediatric indications when used separately (for example, rosuvastatin alone is approved for certain pediatric patients aged 7 years and older with heterozygous familial hypercholesterolemia, and ezetimibe alone has been used in select pediatric patients aged 10 years and older in combination with a statin under specialist care); however, this does not extend to the fixed-dose Rostab EZ product, which should be avoided in children pending further data.